Cefiderocol PK in Patients on ECMO
Key facts
- Who runs it
- Joseph L. Kuti, PharmD
- Where
- Hartford and New York, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 5 people enrolled
- Started
- 16 Jul 2021
- Ended
- 1 Sept 2024
- Type of study
- Interventional
- Treatments tested
- Cefiderocol
- Record updated
- 16 December 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- 18 years of age or older
- On support with veno-venous- or veno-arterial-ECMO
Who cannot take part
- Receiving Cefiderocol to treat documented or suspected infection within 72 hours of screening, or expected to receive Cefiderocol during the study intervention phase
- Severe renal dysfunction defined as a CrCL < 15 mL/min (as calculated by the Cockcroft Gault equation using actual body weight) or requirement for continuous renal replacement therapy or hemodialysis
- History of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic (a history of mild rash to a cephalosporin followed by uneventful re-exposure is not a contraindication)
- Any rapidly progressing disease or immediately life-threatening illness (defined as imminent death within 48 hours in the opinion of the investigator)
- Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of study data
- A hemoglobin less than 7.2 gm/dl at baseline
- Acute liver injury, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal, or AST or ALT > 3 times the upper limit of normal with an associated total bilirubin > 2 times upper limit of normal
- Females who are pregnant or breast-feeding
Where in United States
- Hartford HospitalHartford, United States
- Columbia University/New York Presbyterian HospitalNew York, United States
About the trial
What the trial wants to find out
Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, Cefiderocol, in critically ill patient receiving ECMO.
The group in the trial
- CefiderocolTreatment being tested
Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ex Vivo Sequestration and Pharmacokinetics of Cefiderocol in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
- Record updated
- 16 December 2024